Cross-Sector entity
Arm's-length lenders is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is fda-approval: 1 of 4 stories, with the rest divided among 3 other categories. The tracked stories average 4 original sources each.
4 verified stories tracked
Last mentioned: Jun 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Arm's-length lenders is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is fda-approval: 1 of 4 stories, with the rest divided among 3 other categories. The tracked stories average 4 original sources each. OTCQB appears in 4 tracked Cross-Sector stories from June 21, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OTCQB. Shared-story counts are live from our verified record — not editorial picks.
Share Hold Period Expires
Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws.
Anticipated Settlement Date
Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash.
Debt-for-Equity Agreements Signed
DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance.
Startup DIAGNOS, building AI eye diagnostics, used a shares-for-debt settlement to preserve cash and extend its operating runway. The deal adds 625,000 shares at C$0.20 each, showing how early-stage companies can renegotiate obligations to survive.
DIAGNOS announces a C$125K debt settlement through issuance of common shares at C$0.20, a move that conserves cash but dilutes existing shareholders. The transaction awaits TSX Venture approval and introduces a four-month hold period.
Biotech company DIAGNOS executes a small debt-for-equity swap, preserving liquidity to sustain its AI-based early detection platform for critical eye conditions. The move reflects the tight capital environment for early-stage diagnostic innovators.
Diagnos Inc. converts C$125K in debt to equity, preserving cash to further develop its AI-powered early detection of eye-related health issues. The move underscores the financial pressures on health AI startups but keeps the clinical mission on track.
Source: shorelinebeacon.com · pembrokeobserver.com
